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Accepted 23 December 2009Ascites and pleural effusion are common but are serious
complications of ovarian hyperstimulation syndrome (OHSS).
In critical cases of this syndrome, multiple paracenteses may
be required to relieve the severe abdominal distention, hypo-
tension, decreased renal perfusion, and severe respiratory
compromise that can arise [1]. Continuous abdominal and
pleural drainages are indicated in cases of massive ascites and
pleural effusion [2]. However, the complications associated
solely with the performance of paracentesis are infrequently
reported. Furthermore, a clinical dilemma arises when patients
with von Willebrand’s disease (vWD) develop OHSS such that
repeated abdominal paracentesis is required. vWD is the most
common congenital hemorrhagic diathesis inherited as an
autosomal dominant trait; the prevalence of this disease is
estimated to be 1e2% of the population [3]. Mucocutaneous
and surgical hemorrhage in affected individuals is caused by
quantitative or qualitative defects in von Willebrand factor
(vWF). This large multimeric protein supports platelet adhe-
sion and aggregation during initiation of hemostasis at the
time of vascular injury and functions as a carrier protein for
circulating factor VIII [4].
In the present report, a patient with Type II b vWD and
severe OHSS complicated by multiple skin ecchymosis and
subcutaneous hematomas after performance of multiple para-
centeses is described. Conservative treatment with parenteral
administration of albumin and Haemate-P combined with
a platelet transfusion served to prevent the serious sequelae of
coagulopathy.
A 31-year-old infertile nulligravida woman with history of
Type IIb vWD requested assisted intrauterine sperm insemi-
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(PCOS). Pituitary downregulation with buserelin acetate
(Suprefact; Hoechst, Germany; 0.5 mg/d) was initiated on
Days 2, 3, and 4 of her menstrual cycle followed by ovarian
stimulation with a daily dose of 225 IU of subcutaneous
Gonal-F for 6 days. At 12 days following initiation of ovarian
stimulation, the patient developed eight dominant follicles
ranging between 18 mm and 21 mm in diameter, and a peak
serum estradiol concentration of 2,626 pg/mL was observed
on the day of injection of 5,000 IU of human chorionic
gonadotropin (hCG; Profasi; Serono Laboratories, Norwell,
MA, USA). A standard intrauterine insemination was per-
formed 36 hours later. Luteal phase support was provided by
administration of Utrogestan (100 mg, three times daily, by
vaginal suppository) with another intramuscular injection of
2,000 IU of hCG given on the 22nd cycle day.
The patient complained of acute abdominal distension,
nausea, and vomiting; and 3.5 kg body weight gain were
observed on the 25th cycle day. Severe OHSS was diagnosed
on the basis of enlarged ovaries as observed by ultrasound and
on the bases of massive ascites and pleural effusion as
observed by plain chest film. Hemoconcentration and hypo-
albuminemia were diagnosed by increased hematocrit (48.5%)
and hemoglobin (18.5 g/dL) values in addition to a decreased
albumin value (3.1 g/dL; normal reference, 3.5e5.3 g/dL).
The prothrombin time (12.0 seconds) and the activated partial
thromboplastin time (24.5 seconds) were both within normal
limits.
The patient was treated with a large volume of plasma
expander, and 100 g of human serum albumin was adminis-
tered daily. Four attempts at abdominal paracentesis were
performed to relieve dyspnea and abdominal distension, with
up to 1,840 mL; 2,300 mL; 1,400 mL; and 1,100 mL of ascitic
fluid drained between the 2nd and 6th hospital day. Thor-
acocentesis was withheld because of thrombocytopenia, with
platelet counts as low as 25,000/mm3 obtained on the 4thcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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values were: hemoglobin, 13 g/dL; prothrombin time, 12.3
seconds (control, 13.0 seconds); activated partial thrombo-
plastin time, 26.7 seconds (control, 36 seconds); bleeding
time, 8.0 minutes (normal reference, 2 7.5 minutes). All
vWF factor measurements were within the reference range of
132% (normal reference range: 60 150%). On hospital Day
7, symptoms of OHSS improved; however, she developed
multiple ecchymoses over her tapping sites. These ecchymoses
coalesced into subcutaneous hematomas measuring
40 50 cm2 in size. Following intravenous administration of
50 IU/kg of Haemate-P (factor VIII concentrate), hemostasis
was restored. Her bleeding time returned to the normal range,
which remained for the rest of her hospital stay. She was
discharged on the 16th hospital day.
After a successful intrauterine insemination, a twin preg-
nancy was confirmed at gestational Week 6. However,
a miscarriage of one embryo occurred at the 7th gestational
week. The remaining male singleton was delivered unevent-
fully by the vaginal route at the 40th gestational week.
Haemate-P replacement therapy was administered during the
first stage of labor and was given continuously in combination
with uterotonics for 3 days after delivery to avoid a bleeding
episode. Following these treatments, a normal coagulation
profile was achieved. Neither an immediate vaginal hematoma
nor a late postpartum hemorrhage occurred following delivery.
Cases of acquired vWD of the Type IIb variety combined
with OHSS have been reported only rarely. Type IIb vWD is
attributable to a qualitative abnormality in the region of vWF
responsible for the rapid clearance of its multimeric forms.
These abnormal multimeric forms bind tightly to platelets,
which are then rapidly cleared such that thrombocytopenia may
occur. Most cases are associated with mucosal bleeding and
present with epistaxis, gingival bleeding, or menorrhagia.
The patient described in the present report denied having any
incisional bleeding after surgery or dental extractions before
admission. Laboratory findings for patients with Type IIb vWD
include a normal platelet count and morphology, although
bleeding time for these patients is usually prolonged. Because of
the subclinical presentation of our patient, her bleeding timewas
not determined before induction of ovulation.
The clinical management of pregnancy and delivery for
patients with Type IIb vWD is well described in the literature,
and only one case of acquired hemophilia in the presence of
OHSS has been reported [5]. Hemophilia was diagnosed on
the basis of a reduction in factor VIII:C; all measurements
related to vWF (factor VIII antigen, ristocetin cofactor
activity) were normal. In the present case, the possibility of
acquired hemophilia was excluded because factor VIII:C
concentrations were within the normal range. Our patient also
had normal vWF concentrations, consistent with the presence
of the IIb subtype, which is associated with changes in the
quality, as opposed to the quantity, of vWF.
Our patient exhibited bleeding times of up to 8 minutes in
the absence of aspirin therapy. The reports of cases of
thrombophilia caused by OHSS [6] contrast markedly with the
present report in which severe thrombocytopenia (plateletcount of 2.5 104/mm3) was observed. That the thrombocy-
topenia was attributable to an increased binding of large
multimeric forms of vWF to platelets such that the complexes
were more rapidly consumed could not be established. Further
studies are required to understand more fully the pathophysi-
ology underpinning the relationship between OHSS and vWD.
In cases of PCOS, prolonged treatments with high doses of
FSH may serve to induce OHSS. Based on the body weight
(65 kg) of our patient, a daily dose of 225 IU FSH was
required for the initial induction of ovulation; this treatment
may therefore have been responsible for the development of
her OHSS. It is also important to note that hCG should be
withheld from PCOS patients during the luteal phase to avoid
provoking severe OHSS. Furthermore, luteal phase adminis-
tration of hCG is associated with a higher incidence of severe
OHSS as compared with supplementation with progesterone
alone [7]. Patients with PCOS should be informed of the high
risk of OHSS before induction of ovulation.
The standard therapy for patients with vWD is a transfusion
of plasma cryoprecipitate. Each unit of cryoprecipitate will
raise vWF values approximately by 3%, and 10e15 units of
cryoprecipitate may elevate vWF values by as much as
30e50%. Factor VIII antigen concentrations decline with
a half-life of 12e18 hours, but the duration of the corrected
bleeding time is usually shorter. New factor VIII concentrates,
such as Haemate-P, that are now broadly available are antic-
ipated to replace cryoprecipitate as the treatment of choice for
patients with vWD [8,9]. Recommended dosages of these
concentrations are 20e50 units/kg, depending on disease
severity. In the case of our patient, Haemate-P was adminis-
tered at later times than that are traditionally chosen. To
correct her coagulopathy, a dose of 50 units/kg of Haemate-P
was given on an emergency basis with a good treatment
response. In patients with vWD, a significantly increased risk
for hemorrhage exists during labor and delivery, particularly
during the puerperium. However, vaginal delivery is reported
to be generally free of such risk in patients with vWD [10,11].
The incidence of postpartum hemorrhage for these patients is
30%. The danger of postpartum bleeding complications cannot
be predicted with certainty, either by past history of bleeding
episodes or by laboratory tests designed to measure vWF
activity [12]. Because of our previous success with Haemate-P
in managing iatrogenically induced hematomas because of
multiple abdominal paracenteses, Haemate-P was chosen for
the present case to control bleeding during episiotomy.
In conclusion, patients with severe OHSS superimposed on
vWD and for whom abdominal paracentesis is needed to
relieve massive ascites are at risk for development of diffuse
skin ecchymosis because of an underlying bleeding tendency.
In patients with vWD, measurements of serum prothrombin
time and activated partial thromboplastin time before induction
of ovulation do not adequately evaluate bleeding tendency.
Detailed coagulation profiles should be obtained for infertile
patients with vWD before they undergo assisted reproductive
procedures. Multiple abdominal paracenteses should be with-
held from these patients if the possibility of subcutaneous
hematoma persists.
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